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A superior preparation method for daidzein-hydroxypropyl-β- 
-cyclodextrin complexes with improved solubility and dissolution: 
Supercritical fluid process
Advantages of the supercritical fluid (SCF) process compar­
ed to the conventional solution stirring method (CSSM) in 
the preparation of daidzein­hydroxypropyl­β­cyclodextrin 
(HPβCD) complexes were investigated. Formation of daid-
zein/HPβCD inclusion complexes was confirmed by Fourier 
transformed­infrared spectroscopy (FTIR), differential 
scan ning calorimetry (DSC), X­ray diffraction (XRD) and 
scanning electron microscopy (SEM). Particle size, inclusion 
yield, drug solubility and dissolution of daidzein/HPβCD 
complexes were evaluated. Compared to CSSM, the SCF 
process resulted in higher inclusion yield and higher solu-
bility. Also, extended dissolution of daidzein from the SCF 
processed HPβCD inclusion complexes was observed, with 
only 22.94 % released in 45 min, compared to its rapid re-
lease from those prepared by CSSM, with 98.25 % drug re-
lease in 15 min. This extended release of daidzein from SCF 
prepared inclusion complexes was necessary to avoid drug 
precipitation and improve drug solubilisation in the gastro-
intestinal tract. The results showed that the SCF process is 
a superior preparation method for daidzein­hydroxypropyl­
β­cyclodextrin complexes.
Keywords: daidzein, hydroxypropyl­β­cyclodextrin, super-
critical fluid, inclusion complex
Daidzein (4′,7­dihydroxylisoflavone), isolated mainly from leguminous plants, is a 
natural plant estrogen. It has a wide spectrum of physiological and pharmacological func-
tions, including antifibrotic (1), antiestrogenic (2), anticancer (3, 4), anti­inflammatory (5), 
cardioprotective and enzyme­inhibitory (6, 7) effects. However, the poor aqueous solubil-
ity in the gastrointestinal (GI) tract severely restricts the absorption of daidzein, and there-
by its curative effects (8). Therefore, it is urgent to develop an appropriate method for en-
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One of the most important approaches to improving solubility and oral absorption of 
drugs is the use of cyclodextrins (CDs) (9). CDs are cyclic oligomers of glucose that can 
form water­soluble inclusion complexes with small molecules and portions of large com-
pounds (10). Owing to their good biocompatibility, low toxicity and non­immune respons-
es to animals and humans (11), CDs have been widely used in pharmaceutical applications 
for oral drug solubilisation in the last half century (12). Several techniques, including 
kneading, grinding, freeze drying and crystallization have been used to prepare drug/CD 
inclusion complexes. However, most of these methods require multistage processes, which 
are time­ and energy­consuming, resulting in residual solvents in products. Besides, solu-
bility improvement for poorly water soluble drugs has been limited and severely influ-
enced by preparation methods.
Supercritical fluid (SCF) process is proposed as a novel alternative method for the 
preparation of drug­cyclodextrin complexes. Supercritical carbon dioxide (SC­CO2) is sug-
gested as a new complexation medium instead of other conventional liquid solvents (13). 
In this study, the SCF process was used to prepare daidzein­HPβCD complexes for im-
proving drug solubility. In addition, differences between daidzein­HPβCD complexes in 
improving drug solubilisation and dissolution behaviour by the SCF process and the con-
ventional solution stirring method (CSSM) were compared.
EXPERIMENTAL
Materials
Daidzein (purity 98 %, batch number: Dd20090823) was obtained from Shanxi Zelang 
Phytoextraction Co., Ltd. HPβCD (purity 98 %, batch number: H5F178P) was purchased 
from Wacker Chemical Co., Ltd. Carbon dioxide (Instrument grade, purity 99.5 %) was 
purchased from Zhonghong Industrial Gas Shenzhen Co., Ltd. Ethanol (analytical grade, 
purity 99.7 %) was purchased from the Guangzhou Chemical Reagent 2 Factory. Methanol 
(HPLC grade) was purchased from Merck Co., Ltd.
Preparation by the conventional co-grinding method (CG)
Daidzein and CDs of 1:1 molar ratio were accurately weighed. CD solution was pre-
pared by mixing 584.0 mg CD and 2.4 mL water in a mortar. Then, 101.0 mg of daidzein 
was added. A homogenous paste was prepared and further ground for 30 min. The ob-
tained mass was oven dried at 40 °C for 24 h. It was then washed 3 times with 10 mL an-
hydrous ether, and dried at 40 °C.
Preparation by the conventional co-precipitation method (CP)
Daidzein and CDs of 1:1 molar ratio were accurately weighed. 15 mL of CD solution 
was prepared with 584.0 mg HPβCD and water. Then, 101.0 mg daidzein dissolved in 60 
ml anhydrous ethanol was added slowly and a suspension was formed. The suspension 
was stirred at 40 °C for 30 min and kept under stirring at room temperature for 24 h. The 
obtained mass was filtered through a 0.45 μm membrane filter and oven dried at 40 °C. It 
was then washed 3 times with 10 mL anhydrous ether and dried at 40 °C.
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Preparation by the conventional ultrasonic method
Daidzein and CDs of 1:1 molar ratio were accurately weighed. 10 mL of CD solution 
was prepared with 292.0 mg HPβCD and water. After addition of 50.0 mg daidzein, a sus-
pension was formed. Then, the suspension was stirred in an ultrasonic machine for 5 h at 
100 w. The obtained mass was filtered through a 0.45 μm membrane filter and oven dried 
at 40 °C.
Preparation by CSSM
A sample of 202.0 mg daidzein was added to 10 mL 10 % (m/V) HPβCD aqueous solu-
tion (pH 12.0) with a molar ratio of 1:1. 1168.0 mg HPβCD was dissolved in 10 mL water to 
prepare a 10 % (m/V) HPβCD aqueous solution. Then, this mixture was stirred continu-
ously at 45 °C for 4 h (300 rpm). After cooled to ambient temperature, the suspension was 
filtered through a 0.45 μm membrane filter. After that, the filtrate was lyophilized.
Preparation by the SCF process
A sample of 178.0 mg daidzein and 1002.0 mg HPβCD of a molar ratio of 1:1 were 
ground in a mortar until homogeneous to get physical mixtures. Daidzein/HPβCD 
inclusion complexes were prepared using a supercritical fluid extraction apparatus (Fig. 1). 
Physical mixtures were placed into an extraction vessel (6). The system was then heated to 
200 °C over an oil bath. Valve 8 and valve 2 were opened and the air inside was drained 
due to CO2 influx. Five minutes later, valve 8 was closed, and the CO2 was pumped into the 
vessel. After reaching the desired pressure of 20 MPa, valve 2 was closed. After 8 h, valve 
8 was opened to depressurize the system. The depressurization process was controlled for 
30 s. The whole process was repeated three times. Solubility and yield of the SCF processed 
product were determined.
Characterization of daidzein/HPβCD inclusion complexes 
Solubility determination of inclusion complexes
Solubility and product yield of all the above prepared CD inclusion complexes were 
determined. One gram of inclusion complex product prepared by the above preparation 
methods was first dispersed into 1 mL distilled water. After 24 h, this mixture was filtered 
through a 0.45 μm Millipore filter. The filtrate was then diluted properly and its concentra-
Fig. 1. Schematic drawing of the supercritical fluid extraction apparatus: 1 – CO2 source, 2 and 8 – valves, 
3 – cooler, 4 – pump, 5 – pressure gauge, 6 – extraction vessel and 7 – oil bath.
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tion was measured with Agilent 1200 HPLC. The detective wavelength was 250 nm. The 
mobile phase consisted of methanol and water (55:45). Inclusion yield was then calculated. 
Every measurement was done in triplicate and 3 batches of products were investigated.
Characterization by scanning electron microscopy
The morphology of daidzein, HPβCD, physical mixtures, SCF processed daidzein and 
the complexes prepared by CSSM and SCF process were visualized using a scanning elec-
tron microscope (JSM­6460LV, JEOL, Japan). Samples were coated with gold­palladium 
using a sputter module prior to analysis.
Characterization by differential scanning calorimetry
In order to conduct DSC properly, the decomposition temperatures of daidzein and 
HPβCD were determined using thermogravimetric analysis. Daidzein and the SCF pro-
cessed daidzein were investigated with DSC 204F1 (NETZSCH, Germany). Samples were 
accurately weighed in a DSC aluminium pan and were crimped and then heated under an 
inert nitrogen atmosphere (20 mL min–1) at a scanning rate of 10 °C/min from room tem-
perature to 350 °C. An aluminium pan containing the same amount of aluminium oxide 
was used as reference.
Characterization by powder X-ray diffractometry
X­ray diffraction patterns of daidzein, HPβCD, physical mixtures, SCF processed 
daidzein and inclusion complex products of CSSM and the SCF process were obtained 
using a D/MAX­1200X diffractometer (Science Co., Ltd, Japan). The measuring conditions 
were as follows: Cu­Kα1 radiation source; divergence slit 0.50 mm; receive slit 0.3 mm; 
voltage 35 kV; current 25 mA; 2θ angle from 30 to 600.
Characterization by Fourier-transform infrared spectroscopy
FTIR spectra for daidzein, HPβCD, physical mixtures, SCF processed daidzein and 
inclusion complex products of CSSM and the SCF process were obtained using a FTIR 8400 
spectrometer (Shimadzu, Japan). The samples for analysis were mixed with dry KBr at 
about a 1:100 (sample: KBr) ratio and pressed to form KBr pellets. For each sample, 64 scans 
were collected at a resolution of 2 cm–1 over the wavenumber region of 2500–400 cm–1.
Particle size analysis
Particle sizes of daidzein, HPβCD, physical mixtures, SCF processed daidzein and 
inclusion complex products of CSSM and the SCF process were measured using a laser 
particle size analyser (Mastersizer 2000, Malvern, UK) equipped with Sirocco 2000.
Dissolution rate study
Dissolution rate studies of daidzein alone and from various daidzein­cyclodextrins 
systems were conducted in a dissolution apparatus (RCZ­8A, China) using the paddle 
method, according to USP XXVI at 37 ± 0.5 °C, with stirring at 100 r/min. 3.22 mg of 
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daidzein or an equivalent amount of daidzein­cyclodextrin was added to 500 mL of water. 
5 mL of the solution was taken out and replaced with the same volume of fresh medium 
at 5, 10, 15, 20, 30, 45 min. The withdrawn solution was immediately filtered through a 
0.45 μm membrane filter and suitably diluted. Daidzein concentration in samples was 
determined by HPLC.
RESULTS AND DISCUSSION
Solubility and product yield of inclusion complexes
As shown in Table I, the solubility of CSSM was significantly higher than those of 
other conventional preparation methods. Thus, the CSSM method was deemed to be the 
optimized conventional preparation method. In further studies, a comparison of CSSM­
prepared daidzein/HPβCD inclusion complexes and SCF processed daidzein/HPβCD in-
clusion complexes was conducted. The solubility of SCF processed inclusion complexes 
was 44.81 mg/mL, which was nearly double that of CSSM.









Solubility (mg mL–1) 19.93 ± 2.23 4.54 ± 0.68 0.16 ± 0.08 23.65 ± 3.37
Yield (%) 56.30 ± 8.89 52.86 ± 7.45 85.20 ± 9.63 70.91 ± 8.12
Scanning electron microscopy
The morphology by SEM for daidzein, HPβCD, physical mixtures, SCF processed 
daidzein and inclusion complexes prepared by CSSM and the SCF process is given in Fig. 
2. From SEM analysis, pure daidzein and daidzein processed with SC­CO2 appeared as 
long and thin prismoid crystals, indicating that the daidzein morphology was hardly al-
tered by the SCF process. Pure HPβCD (Fig. 2b) was an irregular spherical particle, while 
physical mixtures (Fig. 2c) showed a blend of spheres of HPβCD and prismoid daidzein 
crystals. Inclusion complex products prepared by both CSSM (Fig. 2e) and the SCF process 
(Fig. 2f) were plate­like and, apparently, the latter was more homogeneous and finer.
Thermal analysis
The thermogravimetric analyser (TGA) graphs for daidzein and HPβCD are repre-
sented in Fig. 3. Daidzein began to decompose at 340 °C, and HPβCD began to decompose 
at 300 °C. Thus, we only presented the DSC measurement of pure and SCF processed 
daidzein. The DSC curves for daidzein (Fig. 4a) and SCF processed daidzein (Fig. 4b) 
showed a characteristic melting endothermic peak when above 337.4 °C. This indicated 
that the SCF process did not change daidzein crystallinity.
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Fig. 2. SEM pictures of different samples: a) daidzein, b) HPβCD, c) physical mixtures, d) SCF pro-
cessed daidzein, e) product prepared by the conventional solution stirring method, and f) product 
prepared by the SCF process.
Fig. 3. TGA graphs of daidzein and HPβCD.




d)                                                   e)                                                   f)
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Powder X-ray diffractometry
The PXRD patterns of raw materials and inclusion complexes are represented in Fig. 
5. The diffraction patterns of daidzein and SCF processed daidzein are similar, and display 
sharp and intense characteristic peaks, confirming the crystallinity of pure daidzein. In 
agreement with DSC analysis, PXRD analysis indicated that the SC­CO2 process did not 
alter daidzein crystallinity. The diffraction pattern of HPβCD displays two broad halos at 
2θ equal to approximately 10o and 18o, confirming its amorphous nature. Physical mix-
tures showed a diffraction pattern similar to that of the respective pure daidzein and 
HPβCD, indicating the existence of crystalline structure of the drug. However, diffraction 
patterns of the complexes prepared by CSSM and the SC­CO2 process were characterized 
by complete disappearance of drug peaks. On the other hand, they displayed two broad 
features similar to that of pure HPβCD, suggesting the possible formation of inclusion 
complexes in which the daidzein was entrapped in the cavity of HPβCD. Besides the inclu-
sion complex formation, daidzein amorphisation could also be due to co­precipitation of 
the binary system leading to amorphous distribution of the drug in HPβCD or inhibition 
of daidzein crystallization in the presence of HPβCD during preparation.
Fourier-transform infrared spectroscopy
The FTIR spectra of the samples are given in Fig. 6. The FTIR spectrum of HPβCD 
showed prominent absorption bands at 3404.1, 2929.7, 2358.8, 2341.4 and 1033.8 cm–1. The 
FTIR spectrum of daidzein consisted of prominent absorption bands with stretching vi-
brations of 2341.4, 1631.7, 1595.0, 1517.9, 1460.0, 1238.2, 1191.9, 887.2, 844.8 and 821.6 cm–1. The 
FTIR spectrum of inclusion complexes prepared by the SCF process (Fig. 6f) is signifi-
Fig. 4. DSC curves of samples: a) daidzein, b) SCF processed daidzein.
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Fig. 5. PXRD patterns of samples: a) daidzein, b) HPβCD, c) physical mixtures, d) SCF processed 
daidzein, e) product prepared by the conventional solution stirring method, and f) product prepared 
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Fig. 6. FTIR spectra of samples: a) daidzein, b) HPβCD, c) physical mixtures, d) SCF processed daid-
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Fig. 7. PSD graphs of samples: a) daidzein, b) HPβCD, c) physical mixtures, d) SCF processed daid-
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Fig. 8. Dissolution diagrams of daidzein, physical mixtures and inclusion complexes in water at 37 °C.
cantly different from those of daidzein (Fig. 6a) and physical mixtures (Fig. 6c). In the FTIR 
spectrum of physical mixtures, the ­CH2 stretch peak (2929.7, 2358.8 and 2341.4 cm
–1) cor-
responded to those of HPβCD (Fig. 6b), while ­C=O vibration peak (1631.7 cm–1) and the 
peaks at 1517.9 and 1460.0 cm–1 corresponded to those of daidzein, suggesting a superposi-
tion of the two compounds. However, compared to pure daidzein, the ­C=O vibration peak 
(1631.7 cm–1) and the characteristic peak of the benzene ring (1595, 1500 and 1460 cm–1) in 
the FTIR spectra of the products prepared by CSSM (Fig. 6e) and the SCF process (Fig. 6f) 
disappeared, and the spectra were very similar to that of HPβCD. This revealed that daid-
zein in the complexes was already entrapped into the cavity of HPβCD of both CSSM and 
the SCF process.
Particle size analysis
Fig. 7 shows the particle size and size distribution (PSD) of different samples. Differ-
ing from the PSD graphs of five other samples, the PSD graph of physical mixtures (Fig. 7c) 
was bimodal, which indicated the coexistence of both daidzein and HPβCD. The average 
particle size of daidzein (Fig. 7a, 8.202 μm) was close to that of SCF processed daidzein (Fig. 
7d, 8.400 μm). The average particle size of the inclusion complex products prepared by 
CSSM (Fig. 7e) was 173.212 μm, and the average particle size of the complexes prepared by 
the SCF process (Fig. 7f) was 32.591 μm, which was much smaller.
Dissolution test
Dissolution diagrams of daidzein and daidzein/CDs in water at 37 °C are shown in 
Fig. 8. The dissolution behaviour of inclusion complexes and physical mixtures was anal-
ysed in comparison with pure daidzein. The results showed that the dissolution of pure 
daidzein was only 5.30 % after 45 min. The dissolution behaviour of physical mixtures was 
very similar to the pure drug, while both inclusion complexes prepared by CSSM and by 
SCF displayed better dissolution properties compared to daidzein alone. However, the 
products prepared by CSSM showed very rapid release, 87.17 % was released in the first 5 
min, and then up to 98.25 % was released in 15 min. In contrast, the products prepared by 
SCF showed sustained release, with only 22.94 % released for 45 min.
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The inclusion complexes processed by SCF showed extended drug release. This was 
necessary for the cyclodextrins­based oral drug delivery system. After oral administration, 
the primary driving force for dissociation of the drug­cyclodextrin complexes is simple dilu-
tion and competitive displacement of the drug by biological components in the gastrointes-
tinal fluid (14). All these factors lead to rapid release of the guest molecule. Too fast release 
of drug molecules from cyclodextrins may induce formation of a precipitate in the GI tract 
due to the low solubility of daidzein in GI fluids. Moreover, it was difficult for the formed 
hydrophobic precipitates to penetrate through the GI mucus layer, which has been high-
lighted as a significant barrier to drug absorption (15). The presence of hydrophobic do-
mains, carboxyl or sulphate groups on the mucin proteoglycans and the flexible nature of 
mucin fibres lead to hydrogen bonding and hydrophobic and electrostatic interactions with 
foreign particulates (16). This effectively immobilizes particles in the superficial layer of the 
mucus. Thus, extended drug release of SCF processed complexes would avoid lipophilic 
daidzein precipitation in the GI tract, which would be a benefit for its penetration through 
the mucus layer absorption barrier, and thus enhancement of further mucosal absorption.
CONCLUSIONS
In this study, the feasibility of the SCF process was investigated for preparing HPβCD 
inclusion complexes of daidzein in order to improve drug solubility. The SEM, DSC, PXRD 
and FTIR data confirmed the formation of daidzein/HPβCD inclusion complexes by the 
SCF process. Compared to the conventional preparation methods, daidzein/HPβCD inclu-
sion complexes prepared by the SCF process achieved higher inclusion yield and drug 
solubility as well as extended drug release. This is very important for drug solubilisation 
in the gastrointestinal tract and for its further absorption. Therefore, our results show that 
the SCF process, as a one­step cyclodextrin inclusion complex preparing process, provides 
a promising contribution to improving inclusion yield and drug solubility.
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